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Abstract
Introduction: Purpura fulminans (PF) is a devastating complication of uncontrolled systemic inflammation,
associated with high incidence of amputations, skin grafts and death. In this study, we aimed to clarify the clinical
profile of pediatric patients with PF who improved with protein C (PC) treatment, explore treatment effects and
safety, and to refine the prognostic significance of protein C plasma levels.
Methods: In Germany, patients receiving protein C concentrate (Ceprotin®, Baxter AG, Vienna, Austria) are
registered. The database was used to locate all pediatric patients with PF treated with PC from 2002 to 2005 for
this national, retrospective, multi-centered study.
Results: Complete datasets were acquired in 94 patients, treated in 46 centers with human, non-activated protein
C concentrate for purpura fulminans. PC was given for 2 days (median, range 1-24 days) with a median daily dose
of 100 IU/kg. Plasma protein C levels increased from a median of 27% to a median of 71% under treatment. 22.3%
of patients died, 77.7% survived to discharge. Skin grafts were required in 9.6%, amputations in 5.3%. PF recovered
or improved in 79.8%, remained unchanged in 13.8% and deteriorated in 6.4%. Four adverse events occurred in
3 patients, none classified as severe. Non-survivors had lower protein C plasma levels (P < 0.05) and higher
prevalence of coagulopathy at admission (P < 0.01). Time between admission and start of PC substitution was
longer in patients who died compared to survivors (P = 0.03).
Conclusions: This retrospective dataset shows that, compared to historic controls, only few pediatric patients with
PF under PC substitution needed dermatoplasty and/or amputations. Apart from epistaxis, no bleeding was
observed. Although the data comes from a retrospective study, the evidence we present suggests that PC had a
beneficial impact on the need for dermatoplasty and amputations, pointing to the potential value of carrying out a
prospective randomised controlled trial.
Introduction
Dermal and systemic thrombosis of the microcirculation,
referred to as purpura fulminans (PF), is a devastating
complication of widespread endothelial destruction due
to uncontrolled systemic inflammation, associated with a
high incidence of multiple organ failure, need for ampu-
tations, skin grafts and death. PF most frequently occurs
in the pediatric age group, with a peak incidence in
infants (1 to 3 years of age) and adolescents (16 to
18 years of age). Although most frequently seen in the
context of severe septic shock, in particular in patients
with meningococcemia, PF also occurs in the rare sce-
nario of homozygous or double heterozygous protein C
(PC) deficiency [1]. Indeed, the clinical manifestation of a
severe PC deficiency in the form of PF has resulted in the
description of PF as the clinical symptom of an acute PC
pathway failure [2]. Consequently, many intensivists have
used PC substitution in patients with PF, mostly with
promising results [3-6]. The biological rationale for
this use was the anti-coagulant, anti-inflammatory,
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action of PC [7-10].
This retrospective multi-centered study analyzes clini-
cal features, safety and outcome in 94 pediatric and
adolescent patients with PF who received a human non-
activated PC concentrate as rescue therapy in Germany
from 2002 to 2005. In this study, we aimed to clarify the
clinical profile of pediatric patients with PF who
improved with PC treatment, explore treatment effects
and safety, and to refine the prognostic significance of
PC plasma levels. Finally, this study will help to establish
hypotheses and endpoints for future prospective studies
on human PC in patients with PF.
Materials and methods
The ethics committee of the J.W. Goethe University,
Frankfurt, Germany, approved the study protocol for
this retrospective, multi-center study. Patients who
received a human plasma-derived, virus-inactivated PC
concentrate (Ceprotin
®, B a x t e rA G ,V i e n n a ,A u s t r i a )i n
G e r m a n yw e r er e g i s t e r e db yt h em a n u f a c t u r e rd u et oa
post-marketing commitment requested by the European
Medicines Agency. This German database was used to
locate all pediatric patients treated with PC concentrate
from 2002 to 2005. The flow of the patients throughout
the study is displayed in Figure 1. If a patient who
received PC concentrate was identified, the principal
investigator contacted the treating physician with an
invitation to participate in the study. If the treating
physician agreed to participate, the hospital was visited
by a medical monitor (physician) for standardized
(form-based clinical reporting) data collection. For ana-
lysis, patients were stratified into three outcome groups
by survival to hospital discharge and complications
(negative outcome = death and/or amputation; inter-
mediate outcome = survival with skin grafts/dermato-
plasty; positive outcome = survival without amputations
or skin grafts). As data were collected on anonymous
forms, the ethics committee waived the need for
informed consent by the patient or relatives.
Statistics
Descriptive statistics were used for categorical (tables,
rates, 95% confidence intervals (CI)) and continuous
(quartiles, minimum, maximum, mean, standard devia-
tion) variables. Differences in categorical variables
between groups were tested by the chi-square test.
Differences in continuous variables between groups
were tested by the non-parametric Mann-Whitney U
test. Comparisons of relevant parameters were per-
formed between survivors and non-survivors. The rele-
vance of PC plasma levels at admission on the
probability to survive the disease was assessed by a
logistic regression and an odds ratio was calculated to
quantify the influence of the level of PC plasma activity
at admission on survival to discharge.
Results
Demographics
Of the 102 patients located, 94 entered the final analysis
(Figure 1): 52 (55.3%) were male and 42 (44.7%) female;
8 (8.9%) were newborn (< 28 days old), 36 (38.3%) were
Figure 1 Flow of patients through the study and exclusions of patients. The diagnosis of purpura fulminans (PF) was regarded as definite
in the presence of livid to partly necrotic lesions of irregular shape and with sharp, clearly defined borders with either rapid progression or
already ubiquitous appearance. The diagnosis of PF was regarded as probable in the presence of livid to partly necrotic lesions of irregular shape
and with sharp, clearly defined borders. The diagnosis of PF was regarded as unclear in the presence of just livid to partly necrotic lesions
without any of the other criteria. The diagnosis of PF was not confirmed in any patient with lesions not fulfilling the above defined criteria. PC,
protein C.
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Page 2 of 7infants (28 days to 2 years), 29 (30.9%) were children
(2 to 12 years) and 21 (22.3) were adolescents (12 to
18 years).
Patients were treated in 46 different centers, with
36 centers treating 2 or less patients and 10 centers
treating 3 or more patients. None of the centers partici-
pated in or recruited pediatric patients for treatment
studies with activated PC at the time of this study.
Origin of PF
PF was the result of acquired sepsis rather than conge-
nital PC deficiency in all patients. Neisseria meningitides
was isolated in 75 (79.8%) patients, in 52 of those whose
sero-groups were specified.
Survival and outcome of PF
Twenty-one (22.3%) patients died at a mean duration of
two days, and 73 (77.7%) patients survived to discharge.
There was no significant difference in age or gender
between survivors and patients who did not survive.
Skin grafts were required in nine (9.6%) and amputa-
tions in five (5.3%) patients.
PF recovered or improved in 75 (79.8%) patients,
remained unchanged in 13 (13.8%) patients and deterio-
rated in 6 (6.4%) patients.
Shock
At admission, no difference in mean arterial pressure
was detected between survivors and non-survivors (med-
ian 61.5 vs. 70 mmHg, P = 0.168). However, already at
admission, survivors presented with lower heart rates
(median 150 vs. 185 bpm, P = 0.0132) higher Glasgow
coma scale scores (mean 12.5 vs. 9.9, P = 0.027) and
less negative base excess compared with non-survivors
(median -4.95 vs. -11.85 mmol/l, P = 0.021).
A total of 63 patients received inotropic support for a
median duration of two days.
Protein C treatment
Non-survivors had significantly lower PC plasma activity
at admission than survivors (median 10 vs. 30%, P =
0.011). A higher level of PC plasma activity by 1% at
admission improved the odds to survive significantly
(P = 0.0285) by a factor of 1.06 (95% CI for odds ratio =
1.01 to 1.12). PC was given for a median of 33 hours
(range 1 to 645 hours) with a median daily dose of 100
IU/kg (range 28 to 375 IU/kg). PC was administered as
a bolus every four to six hours in 78 patients, and as an
initial bolus followed by continuous infusion in the
remaining 16 patients. There was no significant differ-
ence in survival between the bolus group (21.8% died)
and the bolus plus infusion group (25.0% died;
P = 0.961). Plasma PC levels increased from a median of
27% (range 1 to 75%) prior to PC treatment to a median
of 71% under treatment (range 14 to 184%, Table 1).
Once under PC substitution, there was no significant
difference in plasma PC levels between survivors and
non-survivors (P = 0.605).
The time interval between admission and the start of
PC substitution was significantly longer (median 8.6 vs.
4h o u r s ,P = 0.03) in patients who died compared with
those who survived, and also longer in patients who had
amputations and/or died compared with those who fully
recovered (median 9.25 vs. 4 hours, P = 0.016).
Inflammatory response
C-reactive protein (CRP) levels were significantly lower
at admission in non-survivors compared with survivors
(Median: 5.9 vs. 11.6 mg/dl, P = 0.002). White blood
cell counts were also lower on admission and during
treatment in the non-survivors, but this trend did not
reach statistical significance (Table 1).
Coagulopathy
Non-survivors showed a significantly higher prevalence
than survivors of coagulopathy with prolonged activated
partial thromboplastin time (aPTT) at admission (median:
108 vs. 52 seconds, P < 0.0001). A significantly higher rate
of coagulopathy was still documented with PC treatment
in the non-survivors (Table 1). The platelet count did not
differ significantly at admission between survivors and
non-survivors; however, during treatment, survivors
showed significantly higher platelet counts than patients
who died (median: 103 vs. 61 G/l, P = 0.0047).
Fresh frozen plasma
Of the 94 patients, 71 received fresh frozen plasma
(FFP): 45% received one FFP transfusion, 30% two and
25% received three or more FFP transfusions. The total
amount of FFP given was 33.3 ml/kg in patients being
transfused, on day one a median of 20 ml/kg, on day
two a median of 22 ml/kg and on day three a median of
13 ml/kg. There was no difference in survival between
those patients transfused compared with those who did
not receive FFP (P = 0.345). However, there was a trend
towards a better survival in those patients receiving high
volume (≥ 25 ml/kg/d) FFP on day one compared with
those who received less or no FFP (P = 0.069).
Length of stay and mechanical ventilation
Length of stay on the ICU was a median of eight days
(1 to 95 days) in the whole group, a median of two days
for non-survivors and a median of nine days for survi-
vors (P < 0.0001). The duration of mechanical ventila-
tion was a median of 6.5 days for those who survived.
Survivors were discharged out of hospital after a median
of 18 days, and non-survivors had a median hospital
stay of 2 days.
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Page 3 of 7Table 1 Clinical and laboratory parameters of all patients, survivors, non-survivors before and during treatment with
protein C concentrate
All Survived
(n = 73)
Died
(n = 21)
P
Male/female
(n)
52/42 42/31 10/11 n.s.
Age
(years)
2.46 2.93 1.69 n.s.
PC treatment
PC total dose
(IU/kg)
258.8 (127.6-410.9) 277.8 (132.4-444.4) 153.8 (126.0-375.0) n.s.
PC daily dose
(IU/kg/d)
100 (73.4-136.6) 100
(78.74-133.3)
81.08 (71.09-153.8) n.s.
PC therapy duration (d) 2
(1-4)
3
(2-4)
2
(1-4)
n.s.
Bolus/
Bolus + cont. inf.
78/16 61/12 17/4 n.s.
Haematological paramenters prior to PC treatment
WBC
(pl)
10.4
(5.0-17.02)
11.3
(5.3-18.7)
7.21
(4.6-10.75)
n.s (0.062)
CRP
(mg/dl)
10.48
(5.65-16.47)
11.6
(7.81-17.31)
5.9
(1.99-8.92)
0.0018
Platelets
(G/l)
110
(66-183)
116
(74-182)
78
(52-178)
n.s.
PT
(%)
41
(32-54)
44
(33-56)
31
(22-36)
< 0.001
aPTT
(sec.)
59
(43-91)
52
(39-71)
108
(81-160)
< 0.001
Fibrinogen
(mg/dl)
270
(174-440)
347
(217-503)
129
(82-202)
< 0.001
D-Dimers
(mg/l)
2.38
(0.93-8.99)
2.13
(0.89-8.62)
6.40
(1.08-12.00)
n.s.
AT
(%)
76
(57-87)
80
(60-88)
70
(46-80)
n.s.
PC
(%)
27
(14-39)
30
(18-41)
10
(10-18)
< 0.05
Haematological parameters during PC treatment
WBC
(pl)
21.25
(12.75-27.28)
23.65
(13.65-28.75)
16.35
(7.7-20.90)
< 0.05
CRP
(mg/dl)
14.70 (7.0-21.8) 15.91
(7.1-23.64)
9.36
(6.90-15.88)
n.s.
Platelets
(G/l)
96
(57-130)
103
(65.5-136.5)
61
(30-80.75)
< 0.01
PT
(%)
69
(48.5-87)
77.8
(55-91)
45.5
(37.75-55.75)
< 0.01
aPTT
(sec.)
43
(33-52.75)
41
(33-47)
61
(47.5-88.4)
< 0.01
Fibrinogen
(mg/dl)
558.5
(342-747.2)
600.5
(418-766)
214.5
(184-299.2)
< 0.01
D-Dimers
(mg/l)
1.95
(0.8-6.16)
1.6
(0.68-5.96)
2.93
(1.14-6.4)
n.s.
AT
(%)
87
(68.5-102.2)
87
(68-101.5)
78
(70-102)
n.s.
PC
(%)
71
(53.5-108.4)
79
(54.7-106.8)
68.5
(33.75-108.5)
n.s.
Data on patient characteristics, outcome and laboratory findings. Shown as median and inter-quartile range (range between first and third quartile). Note that
not all laboratory parameters could be obtained in all patients at each time-point.
aPTT, activated partial thromboplastin time; AT, antithrombin; CRP, C reactive protein; n.s., not significant; PC, protein C; PT, prothrombin time; WBC, white blood
cell count.
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Four adverse events were reported in three patients.
None was classified as severe by the treating physician
(two events of hemorrhage from nose and/or throat,
one event of pleural effusion, one event of transient
increase in body temperature). The first patient with an
adverse event developed bleeding from the nose six
hours after receiving 66 IU/kg PC. The bleeding stopped
spontaneously after one hour and the patient received
the next scheduled dose two hours after the onset of the
event without further complications. The treating physi-
cian classified the severity as moderate and causative
relation to PC treatment as unknown. The second
patient was a severely coagulopathic child, who devel-
oped hemorrhage from the throat and nose immediately
after a difficult endo-tracheal intubation approximately
13 hours after receiving 83 IU/kg PC. The patient
received the next dose as scheduled four hours after the
event without further complications. The same patient
developed a pleural effusion (serious with later blood
staining) more that 24 hours after the PC therapy was
ceased. The treating physician classified the severity of
both events as moderate, a causative relation to PC
treatment as unlikely. A third patient showed a transient
(10 minutes) and minor increase in body temperature
(from 39.0°C to 39.5°C) shortly after receiving 100 IU/kg
PC. No treatment was required; the treating physician
classified the severity as mild.
Discussion
Here we report what is to date the largest series of
pediatric patients with PF, as a consequence of acute PC
pathway failure in sepsis, treated with PC concentrate.
In the majority of patients, the underlying infection was
identified as meningococcemia. PC substitution was well
tolerated, safe and the need for amputations and skin
grafts with 5.3% and 9.6%, respectively, both markedly
lower than previously reported in children with PF.
PF, if associated with septic shock, is a devastating dis-
ease carrying a high mortality and significant morbidity.
Although improvement in health care delivery for these
very sick patients has dramatically improved survival in
recent years [11,12], permanent disability as a result of
amputation of limbs or digits, extensive scarring, or neu-
rological injury remains problematic. Gurgey and collea-
gues reported a series of 16 children; nine (69%) of the
13 children aged 4 years or younger and one of the
older children (age range 9 - 12 years) (33%) required
amputation [13]. A case series by Wheeler and collea-
gues on 21 patients reported amputations in nine (43%)
patients [14]. Recent data from Rotterdam reports
amputations in 8%, skin grafts in 16% and skin scarring
in 48% of survivors of meningococcal disease with PF,
combined with orthopedic sequelae in 14% [15]. These
patients did not receive PC. In five patients treated in a
burn center including therapy with activated PC, an
impressive 100% survival was achieved; however, ampu-
tations were still needed in two of the five children
(40%) [16].
We and others have previously described replacement
therapy with human, non-activated PC in patients with
meningococcemia in case reports and smaller case series
[3,4,6,17-19]. Other studies have explored the use of
activated PC in patients with PF. Vincent and colleagues
published a post-hoc analysis of recent studies using
activated PC in adult and pediatric patients with severe
sepsis, presenting with PF, meningitis or meningococcal
disease [5]. The authors identified 119 pediatric patients
suitable for the analysis, 87 of them with PF. In that
group, which had a comparable incidence of coagulopa-
thy and low PC plasma levels, but a slightly more severe
thrombocytopenia compared with the group reported
here (85; 42 to 122 vs. 110; 66 to 183 G/l median; first
to third quartile), serious bleeding events were noticed
in two patients during the infusion and in six patients
over a 28-day period. Fourteen-day mortality was 9.4%,
which is probably lower than the 22.3% in-hospital mor-
tality in the group reported here. It is difficult to com-
pare the illness severity of these two groups, because
Vincent and colleagues did not report the rates for
amputation or skin grafts. Another study, investigating
the use of activated PC in children with severe sepsis,
which was terminated prematurely due to lack of effi-
cacy, showed an increased rate of hemorrhage in the
activated PC compared with the placebo group, espe-
cially in children younger than 60 days [20].
In contrast, significant bleeding complications were
not seen in our large group of pediatric patients and
have also not been associated with the use of human,
non-activated PC concentrate in adult studies so far.
As published previously, this study confirmed low
plasma PC levels to be associated with negative outcome
[21]. In fact, even a difference as small as 1% in PC
plasma activity at admission changed the odds of survi-
val significantly. For a number of medical conditions,
minimizing the amount of time from patient presenta-
tion to initiation of treatment represents an important
consideration in the improvement of treatment out-
comes. Analysis of a large, hospital-level database sug-
gested that earlier treatment with activated PC is
associated with a lower in-hospital mortality in patients
(n = 1179) with severe sepsis [22]. Another retrospective
study, analyzing adults with severe sepsis and APC treat-
ment found an increase in mortality from 33% if treated
on the day of diagnosis to 40% if treatment was delayed
by one day and to 52% if treatment was delayed by two
days or more [23]. In our analysis, the interval between
admission to ICU and the commencement of PC
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w h od i e dc o m p a r e dw i t ht h o s ew h os u r v i v e d ,w h i c h
may point towards the benefits of early therapy in this
rapidly progressive condition.
During PC therapy, coagulatory and inflammatory
markers may be important prognostic markers. The pre-
valence of ongoing coagulopathy, as reflected in a signif-
icantly more abnormal aPTT and prothrombin time,
and in significantly lower fibrinogen levels at admission
and during therapy, was higher in non-survivors com-
pared with survivors. During therapy, but not at admis-
sion, platelets were found to be significantly lower in
p a t i e n t sw h od i dn o ts u r v i v e ,a l s op o i n t i n gt o w a r d s
ongoing coagulopathy as a negative prognostic marker.
Interestingly, although non-survivors showed lower PC
plasma levels and higher incidence of coagulopathy, the
inflammatory response in terms of CRP levels and leu-
kocytosis was less marked in the non-survivors, which
could imply a degree of immuno-paralysis in those
patients.
Being a retrospective multi-center analysis, the limita-
tions of this study are obvious: the lack of a control
group and a prospective design makes it impossible to
comment of the effects of PC on survival. The patients
were treated in many different centers with a conse-
quently large potential for intra-observer variability. On
the other hand, the fact that even with so many different
centers and protocols involved, the safety profile was
still favorable in this unselected high-risk population is
very encouraging.
Conclusions
This study shows encouragingly low rates of amputa-
tions and skin grafts in a large group of pediatric
patients with PF, combined with improvement or reso-
lution of PF in most of the patients across all pediatric
age groups, with no significant adverse side effects. Our
study supports the biological rationale of human non-
activated PC concentrate as a treatment for severe
acquired PC deficiency, presenting with PF. Future stu-
dies investigating the effect of human, non-activated PC
concentrate should focus on the potential benefit of
early PC therapy in PF, and amputations and skin grafts
as important outcome measures in this condition,
which, despite recent advances in mortality control, still
carries a high risk of disabling long-term morbidity.
Key messages
￿ Low plasma levels of PC are negatively correlated
with survival in patients with PF in the context of
meningococcemia.
￿ In this group of pediatric patients, substitution
with human, non-activated PC concentrate resulted
in an improvement of PF in the majority of patients,
without causing significant bleeding.
￿ The need for amputations and skin grafts was low
compared with historical controls, but there was no
obvious effect on mortality.
￿ Future studies investigating the effect of human,
non-activated PC concentrate should focus on early
PC therapy in PF, with amputations and skin grafts
as important outcome parameters.
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